GlassScriptPhysician profile
Rajesh Sehgal
NPI 1003019571
$3,509.39
in general payments reported to CMS, 2019-2025
20 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.69 · 2020: $23.96 · 2022: $111 · 2023: $2,492 · 2024: $236 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719 · Consulting Fee: $1,600 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.55 |
| Consulting Fee | $1,600.00 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,909.70 | 2023-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $350.63 | 2022-2023 | Enhertu |
| Janssen Biotech, INC. | $145.32 | 2023-2024 | Rybrevant, Erleada |
| Caris Mpi, INC. | $143.91 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $142.65 | 2023-2025 | Opdivo, Eliquis |
| Botanix Sb INC | $137.81 | 2025 | Sofdra |
| Genzyme Corporation | $129.19 | 2023 | |
| Incyte Corporation | $124.99 | 2023 | Jakafi |
| Myriad Genetic Laboratories, INC. | $80.06 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $52.87 | 2023 | |
| Celgene Corporation | $48.66 | 2020-2025 | Reblozyl |
| Daiichi Sankyo INC. | $44.25 | 2023-2025 | Enhertu |
| Clovis Oncology, INC. | $34.69 | 2019 | |
| Merck Sharp & Dohme LLC | $34.16 | 2023 | Keytruda, Lenvima |
| Pharmaessentia USA Corporation | $32.18 | 2025 | Besremi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.21 | 2023 | Monoferric |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Seagen INC. | $18.00 | 2023 | Adcetris |
| Pfizer INC. | $17.60 | 2025 | |
| Tempus Ai, INC | $17.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.